Literature DB >> 29605479

Is accurate contouring of salivary and swallowing structures necessary to spare them in head and neck VMAT plans?

Alexander R Delaney1, Max Dahele2, Ben J Slotman2, Wilko F A R Verbakel2.   

Abstract

BACKGROUND AND
PURPOSE: Current standards for organ-at-risk (OAR) contouring encourage anatomical accuracy which can be resource intensive. Certain OARs may be suitable for alternative delineation strategies. We investigated whether simplified salivary and swallowing structure contouring can still lead to good OAR sparing in automated head and neck cancer (HNC) plans.
MATERIALS AND METHODS: For 15 HNC patients, knowledge-based plans (KBPs) using RapidPlan™ were created using: (1) standard clinical contours for all OARs (benchmark-plans), (2) automated knowledge-based contours for the salivary glands, with standard contours for the remaining OARs (SS-plans) and (3) simplified contours (SC-plans) consisting of quick-to-draw tubular structures to account for the oral cavity, salivary glands and swallowing muscles. Individual clinical OAR contours in a RapidPlan™ model were combined to create composite salivary/swallowing structures. These were matched to tube-contours to create SC-plans. All plans were compared based on dose to anatomically accurate clinical OAR contours.
RESULTS: Salivary gland delineation in SS-plans required on average 2 min, compared with 7 min for manual delineation of all tubular-contours. Automated atlas-based contours overlapped with, on average, 71% of clinical salivary gland contours while tube-contours overlapped with 95%/75%/93% of salivary gland/oral cavity/swallowing structure contours. On average, SC-plans were comparable to benchmark-plans and SS-plans, with average differences in composite salivary and swallowing structure dose ≤2 Gy and <1 Gy respectively.
CONCLUSIONS: Simplified-contours could be created quickly and resulted in clinically acceptable HNC VMAT plans. They can be combined with automated planning to facilitate the implementation of advanced radiotherapy, even when resources are limited.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Contouring; Head and neck cancer; Knowledge-based planning

Mesh:

Year:  2018        PMID: 29605479     DOI: 10.1016/j.radonc.2018.03.012

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

Review 1.  Metrics to evaluate the performance of auto-segmentation for radiation treatment planning: A critical review.

Authors:  Michael V Sherer; Diana Lin; Sharif Elguindi; Simon Duke; Li-Tee Tan; Jon Cacicedo; Max Dahele; Erin F Gillespie
Journal:  Radiother Oncol       Date:  2021-05-11       Impact factor: 6.901

2.  Retrospective Validation and Clinical Implementation of Automated Contouring of Organs at Risk in the Head and Neck: A Step Toward Automated Radiation Treatment Planning for Low- and Middle-Income Countries.

Authors:  Rachel E McCarroll; Beth M Beadle; Peter A Balter; Hester Burger; Carlos E Cardenas; Sameera Dalvie; David S Followill; Kelly D Kisling; Michael Mejia; Komeela Naidoo; Chris L Nelson; Christine B Peterson; Karin Vorster; Julie Wetter; Lifei Zhang; Laurence E Court; Jinzhong Yang
Journal:  J Glob Oncol       Date:  2018-07

3.  Strategies to improve deep learning-based salivary gland segmentation.

Authors:  Ward van Rooij; Max Dahele; Hanne Nijhuis; Berend J Slotman; Wilko F Verbakel
Journal:  Radiat Oncol       Date:  2020-12-01       Impact factor: 3.481

4.  Inter-Observer Variation in Delineating the Pharyngeal Constrictor Muscle as Organ at Risk in Radiotherapy for Head and Neck Cancer.

Authors:  Imran Petkar; Dualta McQuaid; Alex Dunlop; Justine Tyler; Emma Hall; Chris Nutting
Journal:  Front Oncol       Date:  2021-03-09       Impact factor: 6.244

Review 5.  Radiation-Induced Salivary Gland Dysfunction: Mechanisms, Therapeutics and Future Directions.

Authors:  Kimberly J Jasmer; Kristy E Gilman; Kevin Muñoz Forti; Gary A Weisman; Kirsten H Limesand
Journal:  J Clin Med       Date:  2020-12-18       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.